If you're talking about Humana, you're talking about Medicare. If you're talking about Zepbound, you're talking about Medicare. Humana's business is entirely Medicare Advantage these days, so 2026 is the most important year that this question has ever been asked.

In 2026, Humana will cover Zepbound via two paths offered by Medicare. Humana Medicare Advantage drug plans will cover the obstructive sleep apnea indication as of December 2024. The Medicare GLP-1 Bridge pilot kicks in July 1, 2026, to provide coverage for the Zepbound KwikPen with copays of $50 per month for Medicare Part D enrollees with a BMI of 27 or more and a qualifying condition. Except for the Humana Medicare plans, which are based on state's own criteria, almost all Humana members reading this are subject to Medicare regulations.

Each pathway is explained in detail, what those costs are, when they enroll, and what moves they should make before July.

Why Humana Means Medicare Rules

Humana's exit from employer group commercial insurance was focused on Medicare Advantage (one of the two largest MA books in the country), Medicare Part D and state Medicaid programs. This focus makes the Zepbound answer easy: Medicare drug policy is the federal rulebook and 2026 changed it.

Until this year, it was impossible to find Zepbound in the context of weight management, as the weight-loss drug was not covered by Medicare's statutory coverage. The November 2025 federal pricing agreement Axios reported called for a $245 monthly price, and the first weight management coverage in program history (after the original insurer-run design failed to get off the ground, as STAT News chronicled the program's non-participation by insurers), launched as the CMS-run Medicare GLP-1 Bridge.

Pathway One: Sleep Apnea, Coverable Now

The FDA approval for Zepbound for adults with moderate-to-severe OSA and obesity in December of 2024 came without the weight-loss exclusion, and Humana MA drug formularies introduced the medication this year through 2025. Requires a sleep-study confirmed diagnosis, BMI documentation and often CPAP history; prior approval through Humana's pharmacy processes will be completed within the standard Part D time limits (72 hours, 24 expedited).

If you are experiencing OSA symptoms (loud snoring, witnessed apnea, daytime sleepiness) and if you have not been studied, it's a good place to begin: the sleep study is the foundation for everything else, and it is covered diagnostics through your medical benefit. 

Pathway Two: The Bridge Pilot, July 1, 2026

According to NPR, the Medicare GLP-1 Bridge will run from July 1, 2026 to Dec. 31, 2027 and will include the Zepbound KwikPen, Wegovy in both pill and injectable form, as well as the oral Foundayo for weight management. Qualifications include: A BMI of 27 or higher and a qualifying condition (such as heart disease or prediabetes) for enrollment in a Part D plan (which Humana MA-PD plans meet). Copays are capped at $50 per month at the federal price of $245, with the idea of transitioning to a potentially more permanent arrangement in 2028.

There are two preparation moves that are important. Please have qualifying papers (BMI, condition) with you at a visit prior to July. If you are already self-paying for Zepbound, collect starting-weight records, as the prescriber attestation showing that you met the criteria at therapy initiation will keep you in the plan even after you lose weight.

Costs, and the Bridge to the Bridge

In either scenario, the $50 copay cap, the $245 negotiated price, the plan deductible up to $615, and the $2,100 annual Part D out-of-pocket cap are the best in Zepbound's history. Rather, Humana Medicaid members must abide by their state's regulations; approximately 13 states will cover weight-loss GLP-1s and, if covered, nominal copays.

Members who don't have OSA will fill through Lilly's self-pay channel from now to July: self-pay vials at $349 to $499 each month, KwikPens at about $399 to $449, and the federal TrumpRx channel that's also rolling in at about $346 each month. At $50 per month from July, the covered route is better than anything, the self-pay window is measured in weeks now, not years. 

Frequently Asked Questions

Starting July 1, 2026, yes, through the Medicare GLP-1 Bridge pilot covering the Zepbound KwikPen with $50 monthly copay caps for Part D enrollees with a BMI of 27 or higher plus a qualifying condition like prediabetes or heart disease. Before July, weight management alone is not coverable under Medicare rules.

Yes, on Humana Medicare Advantage drug plans, following the December 2024 FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity. The prior authorization needs a sleep-study-confirmed diagnosis, BMI documentation, and often CPAP history, with decisions inside standard Part D timelines.

No more than $50 per month in copays under the federal pricing agreement, after any plan deductible (up to $615), with the $2,100 annual Part D out-of-pocket maximum capping the year. Humana pays the negotiated $245 monthly price. Self-pay bridges before July run $349 to $499 through LillyDirect.

For OSA, submit prior authorization with your sleep study now. For weight management, prepare for the July 1 Bridge opening: your prescriber attests you met the clinical criteria when therapy started, using your starting-weight records, which preserves eligibility even after weight loss. Submit as soon as the program opens, since pilots can cap enrollment.

It follows your state's Medicaid rules rather than Medicare's. About 13 states cover weight-loss GLP-1s with state-specific BMI and program criteria, and the $245 federal price extended to state programs may expand that list through 2026. Check your state plan's preferred drug list or ask Humana member services for your state's criteria.